Get the Stockscreener App
9.31
0.21%
-0.02
After Hours:
9.30
-0.010
-0.11%
Poseida Therapeutics Inc stock is traded at $9.31, with a volume of 1.54M.
It is down -0.21% in the last 24 hours and up +280.00% over the past month.
Poseida Therapeutics Inc is a clinical-stage biopharmaceutical company focused on leveraging non-viral gene engineering technologies to create life-saving therapeutics for patients with a high unmet medical need. It has built a pipeline of autologous and allogeneic chimeric antigen receptor T cell, or CAR-T, product candidates, initially focused on the treatment of hematological malignancies and solid tumours.
See More
Previous Close:
$9.33
Open:
$9.36
24h Volume:
1.54M
Relative Volume:
1.55
Market Cap:
$907.41M
Revenue:
$64.70M
Net Income/Loss:
$-123.43M
P/E Ratio:
-38.79
EPS:
-0.24
Net Cash Flow:
$-95.23M
1W Performance:
+241.03%
1M Performance:
+280.00%
6M Performance:
+223.26%
1Y Performance:
+252.65%
1-Day Range:
$9.31
$9.41
1-Week Range:
$2.77
$9.42
52-Week Range:
$1.87
$9.42
Poseida Therapeutics Inc Stock (PSTX) Company Profile
Name
Poseida Therapeutics Inc
Sector
Industry
Phone
858-779-3100
Address
9390 TOWNE CENTRE DRIVE, SAN DIEGO
Compare PSTX with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
PSTX
Poseida Therapeutics Inc
|
9.31 | 907.41M | 64.70M | -123.43M | -95.23M | -1.38 |
|
VRTX
Vertex Pharmaceuticals Inc
|
468.13 | 120.56B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
750.22 | 82.44B | 13.85B | 4.65B | 3.32B | 40.41 |
|
ARGX
Argen X Se Adr
|
616.55 | 36.87B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
253.07 | 32.64B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
118.39 | 28.38B | 3.30B | -501.07M | 1.03B | -2.1146 |
Poseida Therapeutics Inc Stock (PSTX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jan-04-23 | Initiated | H.C. Wainwright | Buy |
| Jan-07-22 | Initiated | Cantor Fitzgerald | Overweight |
| May-18-21 | Initiated | BTIG Research | Buy |
| Aug-04-20 | Initiated | BofA Securities | Buy |
| Aug-04-20 | Initiated | Piper Sandler | Overweight |
| Aug-04-20 | Initiated | William Blair | Outperform |
View All
Poseida Therapeutics Inc Stock (PSTX) Latest News
Poseida Therapeutics Stock Hits Over 3-Year Highs On Roche’s $1.5B Buyout Deal: Retail Is Euphoric - MSN
Pharma Stock Roundup: RHHBY to Buy PSTX, MRK, AZN See Pipeline Success - MSN
Wall Street Analysts Think Poseida Therapeutics (PSTX) Could Surge 49.25%: Read This Before Placing a Bet - MSN
Should You Buy Poseida Therapeutics, Inc. (PSTX) After Golden Cross? - MSN
Poseida Therapeutics, Inc. (PSTX) Hit a 52 Week High, Can the Run Continue? - MSN
Poseida Therapeutics (FRA:2RZ) Degree of Operating Leverage : -0.28 (As of Sep. 2024) - GuruFocus.com
Poseida Therapeutics, Inc. (NASDAQ:PSTX) Shares Bought by Connor Clark & Lunn Investment Management Ltd. - MarketBeat
Pentwater Capital Management LP Increases Stake in Poseida Therapeutics Inc - GuruFocus.com
Poseida Therapeutics executive chairman sells stock for $278,100 By Investing.com - Investing.com Nigeria
Poseida Therapeutics executive chairman sells stock for $278,100 - Investing.com India
SHAREHOLDER INVESTIGATION: The M&A Class Action Firm Continues to Investigate the Mergers of PSTX, ENLC, BRKH and MNTX - Kilgore News Herald
POSEIDA THERAPEUTICS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Poseida Therapeutics, Inc.PSTX - Business Wire
Roche Holdings, Inc. entered into a definitive merger agreement to acquire Poseida Therapeutics, Inc. from Malin Corporation PLC, Pentwater Capital Management and others for $1.5 billion. - Marketscreener.com
Roche to acquire US-based Poseida Therapeutics - MSN
Advantage Alpha Capital Partners LP Invests $285,000 in Poseida Therapeutics, Inc. (NASDAQ:PSTX) - MarketBeat
Poseida Therapeutics, cell therapy maker, triples on Nasdaq after being acquired by Roche - Kursiv Media
Poseida Therapeutics downgraded to Neutral from Overweight at Cantor Fitzgerald - Yahoo Finance
Roche to acquire cell therapy maker Poseida Therapeutics in $1.5 billion deal - MSN
Poseida Therapeutics (NASDAQ:PSTX) Lowered to "Hold" Rating by Cantor Fitzgerald - MarketBeat
Roche to acquire cell therapy maker Poseida for up to $1.5bn - World Pharmaceutical Frontiers
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates PSTX, ZUO, MNTX on Behalf of Shareholders - GlobeNewswire Inc.
Roche makes takeover bid for Poseida Therapeutics Inc - European Biotechnology News
SHAREHOLDER ALERT: The M&A Class Action Firm Investigates the Me - GuruFocus.com
SHAREHOLDER ALERT: The M&A Class Action Firm Investigates the Merger of Poseida Therapeutics, Inc.PSTX - PR Newswire
Poseida Therapeutics shares skyrocket on acquisition from pharma-giant Roche - Mugglehead
Roche snaps up Poseida for $1.5B - BioWorld Online
Roche rewards Poseida’s shareholders with high premium in $1B takeout - BioCentury
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of - GlobeNewswire
Roche In $1.5 Bn Deal To Buy Poseida Therapeutics - UrduPoint News
Poseida Therapeutics: What The Acquisition Offer Says About Big Pharma Priorities (PSTX) - Seeking Alpha
Roche to Acquire CAR-T Cell Therapy Focused Poseida for $1.5B - MSN
Poseida Therapeutics (NASDAQ:PSTX) Stock Skyrockets on News of Roche Holdings Acquisition - TipRanks
Roche Expands Its Scope in Allogeneic Cell Therapy With $1B Poseida Therapeutics Acquisition - MedCity News
Roche Buys Poseida for up to $1.5B, Leaning Into Off-the-Shelf CAR T - BioSpace
Roche to Acquire Poseida Therapeutics in $1.5B Deal - USA Herald
Why Poseida Therapeutics Stock Is Rising 228% - Barron's
Roche Softens TIGIT Blow With Poseida Buyout - Citeline
Roche to buy cell therapy developer Poseida for $1B - BioPharma Dive
Trending : Roche to Buy Poseida Therapeutics for Up to $1.5 Billion - Marketscreener.com
Roche to acquire Poseida Therapeutics - The Pharma Letter
Poseida Therapeutics (PSTX) Soars Over 223% on Roche Acquisition News - GuruFocus.com
HC Wainwright Reiterates "Neutral" Rating for Poseida Therapeutics (NASDAQ:PSTX) - MarketBeat
Roche in $1.5 bn deal to buy Poseida Therapeutics - Medical Xpress
Poseida Therapeutics stock hits 52-week high at $9.28 - Investing.com
Poseida Therapeutics stock hits 52-week high at $9.28 By Investing.com - Investing.com UK
Poseida shares surge on $1.5 billion Roche acquisition deal By Investing.com - Investing.com Canada
Poseida shares surge on $1.5 billion Roche acquisition deal - Investing.com
Shareholder Alert: Ademi LLP investigates whether Poseida Therapeutics, Inc. is obtaining a Fair Price for its Public Shareholders - The Bakersfield Californian
Roche's Proposed Acquisition Of Poseida Therapeutics Poised To Establish New Core Capability In Cell Therapy For Cancer And Autoimmune Diseases: Details - Yahoo Finance
Poseida Therapeutics downgraded to Neutral from Buy at H.C. Wainwright - TipRanks
Roche to Acquire Poseida Therapeutics in a Deal Worth Up to $1.5 Billion - MSN
Poseida Therapeutics Inc Stock (PSTX) Financials Data
Revenue
Net Income
Cash Flow
EPS
Poseida Therapeutics Inc Stock (PSTX) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Gergen Mark J | Executive Chairman |
Nov 26 '24 |
Sale |
9.27 |
30,000 |
278,100 |
651,291 |
1.61%
1.14%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):